RE
FOLD

RBC Europe’s Amicus Therapeutics FOLD Stock Holding History

RBC Europe’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,193
Closed -$11.6K – 1064
2019
Q4 		$11.6K Sell
1,193
-2,992
-71% -$27.4K ﹤0.01% 772
2019
Q3 		$33.6K Hold
4,185
– – ﹤0.01% 526
2019
Q2 		$52.2K Hold
4,185
– – 0.01% 442
2019
Q1 		$56.9K Hold
4,185
– – 0.01% 430
2018
Q4 		$40.1K Hold
4,185
– – 0.01% 482
2018
Q3 		$50.6K Hold
4,185
– – 0.01% 475
2018
Q2 		$65.4K Buy
+4,185
New +$63.3K 0.01% 420

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RBC Europe's FOLD Position: Q1 2020 in Review

RBC Europe sold out of Amicus Therapeutics (FOLD) in Q1 2020, closing a stake of 1,193 shares — an estimated $11.6K sold.

RBC Europe first reported a position in FOLD in Q2 2018 and held it in 7 quarters. The position peaked at $65.4K in Q2 2018. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • RBC Europe reported no remaining Amicus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • RBC Europe sold 1,193 Amicus Therapeutics shares in Q1 2020, an estimated $11.6K.
  • RBC Europe first reported a position in Amicus Therapeutics in Q2 2018 and held it in 7 quarters.
  • RBC Europe's Amicus Therapeutics position peaked at $65.4K in Q2 2018.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on RBC Europe's 13F filing for Q1 2020, filed 9 Nov 2023.